Therefore, the β-secretase (BACE1: β-site amyloid precursor protein cleaving enzyme 1), which is responsible for initiating the production of Aβ, represents an excellent therapeutic target for the treatment of AD [3], [4], [5], [6]. This evidence concerns the gene BACE1 and Alzheimer disease.